中国药物警戒 ›› 2026, Vol. 23 ›› Issue (3): 343-345.
DOI: 10.19803/j.1672-8629.20250295

• 安全与合理用药 • 上一篇    下一篇

替雷利珠单抗注射液致甲状腺及心脏损害1例分析

张晶1, 杨波1, 杨帅2, 毛美娟2, 姚竞月3, 郭卿2,*   

  1. 1武警特色医学中心药剂科,天津 300162;
    2武警特色医学中心高原高寒环境及心血管病防治研究所,天津 300162;
    3空军军医大学第二附属医院药剂科,陕西 西安 710038
  • 收稿日期:2025-05-16 出版日期:2026-03-15 发布日期:2026-03-17
  • 通讯作者: *郭卿,男,硕士,副主任医师,心血管疾病。E-mail: guoqing1009@sina.com
  • 作者简介:张晶,女,硕士,副主任药师,临床药学与药理学。
  • 基金资助:
    国家自然科学基金资助项目（82304522）

One Case of Thyroid and Cardiac Damage Caused by Tislelizumab Injection

ZHANG Jing1, YANG Bo1, YANG Shuai2, MAO Meijuan2, YAO Jingyue3, GUO Qing2,*   

  1. 1Department of Clinical Pharmacy, Characteristic Medical Center of the Chinese People’s Armed Police Force, Tianjin 300162, China;
    2Institute of Prevention and Treatment of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of the Chinese People’s Armed Police Force, Tianjin 300162, China;
    3Department of Pharmacy, Tangdu Hospital, Xi’an Shaanxi 710038, China
  • Received:2025-05-16 Online:2026-03-15 Published:2026-03-17

PDF (PC)

40

摘要： 目的 分析替雷利珠单抗注射液致甲状腺及心脏严重不良反应病例,为临床安全用药提供参考。方法 讨论1例胆管癌肝转移术后患者使用替雷利珠单抗注射液联合吉西他滨、卡培他滨治疗10周期后发生甲状腺及心脏损害的用药关联性,结合相关文献梳理不良反应临床特征与治疗。结果 结合患者病史、用药史、药品说明书及文献分析,考虑为替雷利珠单抗引起的免疫相关不良事件,表现为甲状腺功能减退、心脏损害（心力衰竭、心室颤动）严重不良反应。给予抗炎、补充甲状腺素、抗心衰、抗心律失常等治疗后,患者甲状腺功能、心功能明显改善。结论 临床上应警惕替雷利珠单抗注射液对甲状腺和心脏损害的潜在不良影响,避免发生严重不良反应,提高用药安全性。

关键词: 替雷利珠单抗, 甲状腺功能减退, 心力衰竭, 心室颤动, 严重不良反应, 免疫相关不良事件

Abstract: Objective To investigate such serious adverse reactions as thyroid and cardiac damage induced by tislelizumab in order to provide a reference for safe medications. Methods One case of thyroid and cardiac damage in a patient with cholangiocarcinoma liver metastasis after 10 cycles of treatment with tislelizumab injection in combination with gemcitabine and capecitabine was discussed. The clinical features and treatment of adverse reactions based on related literature were reviewed. Results Based on the patient’s medical history, medication history, drug prescriptions and literature, this event was assessed as an immune-related adverse reaction caused by tislelizumab, manifested as a series of severe adverse reactions, such as hypothyroidism, cardiac damage, heart failure, and ventricular fibrillation. After anti-inflammatory, anti-heart failure and anti-arrhythmia treatments and thyroid hormone supplementation, the patient’s thyroid function and cardiac function improved significantly. Conclusion Clinicians should be alert to the potential risk of thyroid and myocardial damage induced by tislelizumab so as to prevent deadly serious adverse reactions and ensure the safety of medication.

Key words: Tislelizumab, Hypothyroidism, Heart Failure, Ventricular Fibrillation, Serious Adverse Reaction, Immune-Related Adverse Events (irAEs)

中图分类号: